INKT

MiNK Therapeutics (INKT)

About MiNK Therapeutics (INKT)

MiNK Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of allogeneic invariant natural killer T cell therapies to treat cancer and other immune mediated diseases. The company was founded in 2017 and is headquartered in New York, NY.

Details

Daily high

$12.68

Daily low

$11.55

Price at open

$12.13

52 Week High

$76.00

52 Week Low

$4.56

Market cap

57.2M

Dividend yield

0.00%

Volume

42,701

Avg. volume

20,332

P/E ratio

-4.01

MiNK Therapeutics News